Clinical Trial Detail

NCT ID NCT02908672
Title A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

melanoma

Therapies

Cobimetinib + Vemurafenib

Atezolizumab + Cobimetinib + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST